Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 16/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CASP1 | P29466 | 2/20 | 0.64 |
| ▸ | CASP7 | P55210 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015141 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 | |
| SCHEMBL19850580 | 0.88 | ALDH1A1 (0.79) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 | |
| SCHEMBL2209335 | 0.87 | ALDH1A1 (0.76) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 | |
| SCHEMBL3059418 | 0.84 | ALDH1A1 (0.72) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 | |
| SCHEMBL16134952 | 0.82 | ALDH1A1 (0.69) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 | |
| SCHEMBL12003807 | 0.81 | ALDH1A1 (0.67) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 | |
| SCHEMBL25544341 | 0.81 | ALDH1A1 (0.71) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 | |
| SCHEMBL12830164 | 0.81 | ALDH1A1 (0.67) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 | |
| SCHEMBL2209684 | 0.81 | ALDH1A1 (0.67) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 | |
| SCHEMBL374339 | 0.80 | ALDH1A1 (0.67) | ALDH1A1HSD17B10MAPK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115368301-B | Preparation method of 4-hydroxy-7-methoxyquinoline | 常州琦诺生物科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115368301-A | Preparation method of 4-hydroxy-7-methoxyquinoline | 常州琦诺生物科技有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-115368301-B | Preparation method of 4-hydroxy-7-methoxyquinoline | 常州琦诺生物科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-115368301-A | Preparation method of 4-hydroxy-7-methoxyquinoline | 常州琦诺生物科技有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-9957233-B1 | Process for preparing substituted quinolin-4-ol compounds | CALITOR SCIENCES, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957233-B1 | Process for preparing substituted quinolin-4-ol compounds | CALITOR SCIENCES, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2018026877-A1 | PROCESS FOR PREPARING SUBSTITUTED QUINOLIN-4-OL COMPOUNDS | CALITOR SCIENCES, LLC (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018026877-A1 | PROCESS FOR PREPARING SUBSTITUTED QUINOLIN-4-OL COMPOUNDS | CALITOR SCIENCES, LLC (US) | 2018-02-08 | — | — | WO | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-6867185-B2 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1455809-A2 | INHIBITORS OF HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | ALDH1A1 769/4885HSD17B10 553/4885MAPK1 2557/4885 |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | HAVCR2, LIPC, ZC3HAV1 | ALDH1A1 576/4885HSD17B10 1615/4885MAPK1 2287/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | ALDH1A1 512/4885HSD17B10 735/4885MAPK1 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.